InnoTherapy Inc (246960.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7246960009

Price
2,040.00 KRW
Market cap
69.39 bn KRW
P/E (2025)
–
P/S (2025)
3.15
Dividend yield
0.00 %
Net margin
-17.87 %
Return on equity (ROE)
-16.09 %
Return on assets (ROA)
-4.92 %

InnoTherapy Inc financials

Fiscal year20242025
Revenue4.74 bn KRW22.01 bn KRW
Gross profit1.81 bn KRW4.20 bn KRW
Operating income-3.66 bn KRW-3.40 bn KRW
EBIT-3.47 bn KRW-2.65 bn KRW
Net income-3.73 bn KRW-3.93 bn KRW
Diluted EPS – continuing operations-128.04 KRW-115.66 KRW

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About InnoTherapy Inc

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK and InTro vascular interventional procedure items; and operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024. SCL Science Inc. was founded in 2010 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.